- Home
- DSGX vs LEGN Comparison
DSGX vs LEGN Comparison
Compare DSGX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGX | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 5.9B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DSGX | LEGN |
|---|---|---|
| Price | $85.51 | $21.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $117.11 | $69.58 |
| AVG Volume (30 Days) | 347.9K | ★ 2.5M |
| Earning Date | 12-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.65 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | $703,706,000.00 | ★ $909,045,000.00 |
| Revenue This Year | $12.36 | $68.52 |
| Revenue Next Year | $10.93 | $48.63 |
| P/E Ratio | $48.05 | ★ N/A |
| Revenue Growth | 11.39 | ★ 74.75 |
| 52 Week Low | $78.88 | $20.21 |
| 52 Week High | $124.31 | $45.30 |
Technical Indicators
Market Signals| Indicator | DSGX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 41.71 |
| Support Level | $83.57 | $20.21 |
| Resistance Level | $88.22 | $22.07 |
| Average True Range (ATR) | 1.55 | 0.77 |
| MACD | -0.57 | 0.21 |
| Stochastic Oscillator | 29.38 | 66.67 |
Price Performance
Historical ComparisonAbout DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.